Abselion specializes in the development of biological sensors aimed at the rapid and cost-effective detection of various biological substances, including proteins, DNA, and small molecules. The company's innovative diagnostic analyzers and kits simplify the analysis of these biomolecules, making them valuable tools for pharmaceutical research and manufacturing. By enabling researchers to conduct sensitive, rapid, and near real-time medical diagnoses, Abselion enhances the understanding of biomolecular interactions, particularly in protein interaction analysis. This focus on efficiency and accuracy positions Abselion as a key player in the field of biosensing technology.
IRUBIS GmbH, founded in 2017 and based in Munich, Germany, specializes in the development of mid-infrared (MIR) spectrometers and attenuated total reflection (ATR) crystals. The company focuses on enhancing Fourier transform infrared (FTIR) spectroscopy to improve the analysis of protein-based drugs. Its innovative measurement systems enable real-time bioreactor monitoring, allowing for the online assessment of glucose and lactate levels without contamination risks. IRUBIS also produces a range of ATR crystals, including single-reflection and signal-enhanced varieties, aimed at advancing industry standards for bioprocess monitoring. The company’s technology supports both upstream and downstream bioprocessing, facilitating metabolite monitoring and the detection of target proteins and contaminants through machine-learning evaluation software.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.